Acrux Limited (AU:ACR) has released an update.
Acrux Limited is set to boost its revenue stream with the approval and upcoming launch of Dapsone 7.5% Gel, alongside another product, by early 2025. These launches are part of Acrux’s strategy to expand its portfolio of topically applied pharmaceuticals, which already includes three revenue-generating products in the U.S. market. The company has repaid its Radium short-term facility in full, thanks to a tax rebate, reflecting strong financial management.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
